Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.

ABSTRACT:

Background

The aim of this study was to investigate the clinical value of liquid biopsy as a primary source for variant analysis in lung cancer. In addition, we sought to characterize liquid biopsy variants and to correlate mutational load to clinical data.

Methods

Circulating cell-free DNA was extracted from plasma from patients with lung cancer (n = 60) and controls with benign lung disease (n = 16). Variant analysis was performed using the AVENIO ctDNA Surveillance kit and the results were correlated to clinical and variant analysis data from tumor tissue or cytology retrieved from clinical routine diagnostics.

Results

There were significantly more variants detected in lung cancer cases compared to controls (p = 0.011), but no difference between the histological su

SUBMITTER: Qvick A 

PROVIDER: S-EPMC8254966 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature